Division of Minimally-Invasive Surgical Oncology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore, 3, 20162, Milan, Italy.
IRCCS Humanitas Research Hospital, Unit of Foregut Surgery, Via Manzoni 56, Rozzano, 20089, Milan, Italy.
Gastric Cancer. 2022 Nov;25(6):1105-1116. doi: 10.1007/s10120-022-01321-w. Epub 2022 Jul 21.
Oncologic outcomes after laparoscopic gastrectomy for advanced gastric cancer in the West have been poorly investigated. The aim of the present study was to compare survival outcomes in patients undergoing curative-intent laparoscopic and open gastrectomy for advanced gastric cancer in several centres belonging to the Italian Research Group for Gastric Cancer.
Data of patients operated between 2015 and 2018 were retrospectively analysed. Propensity Score Matching was performed to balance baseline characteristics of patients undergoing laparoscopic and open gastrectomy. The primary endpoint was 3-year overall survival. Secondary endpoints were 3-year disease-free survival and short-term outcomes. Multivariable regression analyses for survival were conducted.
Data were retrieved from 20 centres. Of the 717 patients included, 438 patients were correctly matched, 219 per group. The 3-year overall survival was 73.6% and 68.7% in the laparoscopic and open group, respectively (p = 0.40). When compared with open gastrectomy, laparoscopic gastrectomy showed comparable 3-year disease-free survival (62.8%, vs 58.9%, p = 0.40), higher rate of return to intended oncologic treatment (56.9% vs 40.2%, p = 0.001), similar 30-day morbidity/mortality. Prognostic factors for survival were ASA Score ≥ 3, age-adjusted Charlson Comorbidity Index ≥ 5, lymph node ratio ≥ 0.15, p/ypTNM Stage III and return to intended oncologic treatment.
Laparoscopic gastrectomy for advanced gastric cancer offers similar rates of survival when compared to open gastrectomy, with higher rates of return to intended oncologic treatment. ASA score, age-adjusted Charlson Comorbidity Index, lymph node ratio, return to intended oncologic treatment and p/ypTNM Stage, but not surgical approach, are prognostic factors for survival.
在西方,腹腔镜胃癌根治术治疗进展期胃癌的肿瘤学结果研究甚少。本研究旨在比较属于意大利胃癌研究组的多个中心行腹腔镜和开腹胃癌根治术治疗进展期胃癌患者的生存结局。
回顾性分析 2015 年至 2018 年间手术患者的数据。采用倾向评分匹配法平衡腹腔镜和开腹胃癌手术患者的基线特征。主要终点是 3 年总生存率。次要终点是 3 年无病生存率和短期结果。进行生存的多变量回归分析。
从 20 个中心获得数据。717 例患者中,438 例患者正确匹配,每组 219 例。腹腔镜组和开腹组的 3 年总生存率分别为 73.6%和 68.7%(p=0.40)。与开腹手术相比,腹腔镜手术具有相似的 3 年无病生存率(62.8% vs 58.9%,p=0.40)、更高的回归预期肿瘤治疗率(56.9% vs 40.2%,p=0.001)和相似的 30 天发病率/死亡率。生存的预测因素包括美国麻醉医师协会(ASA)评分≥3、年龄调整Charlson 合并症指数≥5、淋巴结比率≥0.15、p/ypTNM 分期Ⅲ期和回归预期肿瘤治疗。
与开腹手术相比,腹腔镜胃癌根治术治疗进展期胃癌的生存率相似,但回归预期肿瘤治疗的比例更高。ASA 评分、年龄调整 Charlson 合并症指数、淋巴结比率、回归预期肿瘤治疗和 p/ypTNM 分期,但不是手术方式,是生存的预测因素。